0001080014 false 0001080014 2023-11-01 2023-11-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, DC 20549 





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 


Date of Report (Date of earliest event reported): November 1, 2023



(Exact Name of Registrant as Specified in its Charter)


Delaware 000-30319 94-3265960
(State or Other Jurisdiction of
(Commission  File Number) (I.R.S. Employer Identification


1350 Old Bayshore Highway,
Suite 400

Burlingame, California 94010

(650) 238-9600

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices) 


(Former name or former address, if changed since last report) 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   INVA   The NASDAQ Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02. Results of Operations and Financial Condition


On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.


The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 9.01. Financial Statements and Exhibits


(d) Exhibits


99.1   Press Release dated November 1, 2023
104   Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Date: November 1, 2023 By: /s/ Pavel Raifeld
    Pavel Raifeld
    Chief Executive Officer





Exhibit 99.1 




Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress


Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023


Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter


Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023


Repurchased $11.0 million of common stock


BURLINGAME, Calif. – November 1, 2023 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.


· Gross royalty revenue from Glaxo Group Limited (“GSK”) for the third quarter 2023 was $57.0 million, which included royalties of $45.6 million from global net sales of RELVAR®/BREO® ELLIPTA® and royalties of $11.4 million from global net sales of ANORO® ELLIPTA® compared to $65.6 million for the third quarter of 2022, which included royalties of $55.7 million from global net sales of RELVAR®/BREO® ELLIPTA® and $9.9 million from global net sales of ANORO® ELLIPTA®, respectively.


· Net product sales and license revenue for the third quarter of 2023 was $13.7 million, which included $8.0 million from GIAPREZA® net sales, $5.1 million from XERAVA® net sales and $0.6 million from XACDURO® net sales.


· Net income was $82.0 million, or $1.26 basic per share, for the third quarter of 2023, compared to net income of $265.5 million, or $3.81 basic per share, for the third quarter of 2022; the decrease was primarily driven by non-repeated gain on sales of our subsidiary, Theravance Respiratory Company, and its TRELEGY® ELLIPTA® royalty stream in July 2022.


· Cash and cash equivalents totaled $180.0 million. Royalty, product sales and milestone receivables totaled $67.8 million as of September 30, 2023.


"The third quarter of 2023 was marked by significant revenues stemming from our royalty portfolio and solid performance by our internal product portfolio,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “A few weeks ago, we launched XACDURO® in the United States and are encouraged by the market receptivity. Moreover, we announced positive topline data from the Phase 3 trial of our lead pipeline asset, zoliflodacin, and are excited about its potential to affect the treatment paradigm for gonorrhea patients, especially in the presence of antimicrobial resistance concerns. These milestones reinforce the strength and promise of our infectious disease and critical care business.”






Mr. Raifeld concluded, “We continued to exercise cost discipline and saw meaningful operational progress among our investees. In addition, we benefited from significant increases in the equity fair values of our investments. We are confident in the prospects of our business and plan to continue to pursue shareholder-friendly policies, such as share repurchases.”


Third Quarter 2023 and Recent Highlights


GSK Net Sales


·Third quarter 2023 net sales of RELVAR®/BREO® ELLIPTA® by GSK were $303.9 million with $109.5 million in net sales from the U.S. market and $194.4 million from non-U.S. markets.


·Third quarter 2023 net sales of ANORO® ELLIPTA® by GSK were $175.8 million with $89.2 million net sales from the U.S. market and $86.6 million from non-U.S. markets.


Corporate Updates


·During the third quarter of 2023, Innoviva repurchased 856,750 shares of its outstanding common stock for $11.0 million.


·On July 10, 2023, Innoviva’s wholly owned subsidiary, Innoviva Strategic Opportunities, entered into a credit and security agreement with Armata Pharmaceuticals, Inc. (NYSE: ARMP) (“Armata”) and invested $25.0 million to advance Armata’s pipeline of therapeutic phage candidates and support the buildout of its state-of-the art cGMP manufacturing facility.


·On August 21, 2023, Innoviva appointed Stephen Basso as Chief Financial Officer.


Clinical Updates


·In September 2023, Innoviva’s wholly owned subsidiary, Innoviva Specialty Therapeutics, launched XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). XACDURO® is the first and only pathogen-targeted antibiotic and a significant advancement in the way healthcare professionals treat Acinetobacter.


·In November 2023, in collaboration with The Global Antibiotic Research & Development Partnership (GARDP), we announced that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in a global pivotal phase 3 clinical trial for the treatment of uncomplicated gonorrhea, a prevalent disease affecting over 80 million patients a year globally with rapidly rising antimicrobial resistance concerns. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen. In the study, zoliflodacin demonstrated a favorable safety profile and was generally well tolerated, with the majority of adverse events being mild-to-moderate. There were no discontinuations reported due to adverse events, serious adverse events, or deaths.


- 2 -





About Innoviva


Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”). Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.


ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.


Forward Looking Statements


This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.


- 3 -






Condensed Consolidated Statements of Income

(in thousands, except per share data)



   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Royalty revenue, net (1)  $53,558   $62,150   $172,681   $260,429 
Net product sales   13,701    5,107    40,942    5,107 
License revenue   -    -    11,000    - 
Total revenue   67,259    67,257    224,623    265,536 
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)   10,182    3,680    27,910    3,680 
Cost of license revenue   -    -    1,600    - 
Selling, general and administrative   28,636    27,810    71,913    46,084 
Research and development   3,989    11,725    31,566    31,447 
Amortization of acquired intangible assets   6,511    1,511    15,274    1,511 
Gain on sale of Theravance Respiratory Company, LLC (“TRC”)   -    (266,696)   -    (266,696)
Loss on debt extinguishment   -    -    -    20,662 
Changes in fair values of equity method investments, net   (71,980)   (10,298)   (67,886)   44,475 
Changes in fair values of equity and long-term investments, net   2,640    10,168    4,887    23,406 
Interest and dividend income   (4,114)   (2,135)   (11,032)   (3,181)
Interest expense   4,396    5,096    13,205    11,761 
Other expense, net   1,047    (28)   4,289    750 
Total expenses   (18,693)   (219,167)   91,726    (86,101)
Income before income taxes   85,952    286,424    132,897    351,637 
Income tax expense   3,906    57,077    14,706    63,061 
Net income   82,046    229,347    118,191    288,576 
Net income attributable to noncontrolling interest   -    (36,176)   -    6,341 
Net income attributable to Innoviva stockholders  $82,046   $265,523   $118,191   $282,235 
Basic net income per share attributable to Innoviva stockholders  $1.26   $3.81   $1.79   $4.05 
Diluted net income per share attributable to Innoviva stockholders  $0.98   $2.80   $1.45   $3.07 
Shares used to compute basic net income per share   64,953    69,731    66,016    69,640 
Shares used to compute diluted net income per share   86,164    95,830    87,504    95,072 


(1) Total net revenue is comprised of the following (in thousands):


   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (unaudited)   (unaudited) 
Royalties  $57,014   $65,606   $183,049   $270,797 
Amortization of capitalized fees   (3,456)   (3,456)   (10,368)   (10,368)
Royalty revenue, net  $53,558   $62,150   $172,681   $260,429 


- 4 -






Condensed Consolidated Balance Sheets

(in thousands)



   September 30,   December 31, 
   2023   2022 
Cash and cash equivalents  $179,997   $291,049 
Royalty and product sale receivables   67,765    64,073 
Inventory, net   40,515    55,897 
Prepaid expense and other current assets   16,722    32,492 
Property and equipment, net   361    170 
Equity and long-term investments   529,531    403,013 
Capitalized fees   87,239    97,607 
Right-of-use assets   2,828    3,265 
Goodwill   17,905    26,713 
Intangible assets   236,845    252,919 
Deferred tax assets   4,952    - 
Other assets   3,444    4,299 
Total assets  $1,188,104   $1,231,497 
Liabilities and stockholders’ equity          
Other current liabilities  $33,802   $32,322 
Accrued interest payable   833    4,359 
Deferred revenue   1,548    2,094 
Convertible subordinated notes, due 2023, net   -    96,193 
Convertible senior notes, due 2025, net   191,115    190,583 
Convertible senior notes, due 2028, net   254,603    253,597 
Other long term liabilities   68,690    70,918 
Deferred tax liabilities   -    5,771 
Income tax payable - long term   10,020    9,872 
Innoviva stockholders’ equity   627,493    565,788 
Total liabilities and stockholders’ equity  $1,188,104   $1,231,497 


- 5 -






Cash Flows Summary

(in thousands)



   Nine Months Ended September 30, 
   2023   2022 
Net cash provided by operating activities  $107,808   $192,827 
Net cash used in investing activities   (61,610)   (47,956)
Net cash used in financing activities   (157,250)   (45,567)
Net change  $(111,052)  $99,304 
Cash and cash equivalents at beginning of period   291,049    201,525 
Cash, cash equivalents and restricted cash at end of period  $179,997   $300,829 


- 6 -





Investors and Media Contact:
Argot Partners
(212) 600-1902


- 7 -